Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$6.83 USD
+0.10 (1.49%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.84 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Fulcrum Therapeutics, Inc. has a market cap of $364.04M, which represents its share price of $6.73 multiplied by its outstanding shares number of 54.09M. As a small-cap company, FULC's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FULC 6.83 +0.10(1.49%)
Will FULC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
New Strong Buy Stocks for November 12th
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Other News for FULC
RBC Capital Maintains Rating and Raises Price Target for Fulcrum Therapeutics (FULC) | FULC ...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug
FULC Stock: Fulcrum Therapeutics Upgraded to Buy by HC Wainwright | FULC Stock News
Fulcrum Therapeutics (FULC) Receives Upgrade to Buy with Price Target Set at $12